International practice heterogeneity in pre‐transplant management of pulmonary hypertension related to pediatric left heart disease
Pediatric Transplantation · 2023
DOI: 10.1111/petr.14461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2023. Verfasst von Rachel K Hopper und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics (Cardiology), Stanford University School of Medicine, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Heart Transplantation, Heart Failure, Heart-Assist Devices. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Elevated pulmonary vascular resistance (PVR) in the setting of left heart failure may contribute to poor outcomes after pediatric heart transplant (HTx), but peri‐transplant management is variable.
Methods
We sought to characterize international practice by surveying physicians at pediatric HTx centers.
Results
We received 49 complete responses from 39 centers in 16 countries. Most respondents are pediatric cardiologists (90%), practice at centers offering heart (86%) and lung (55%) transplant, and perform pre‐HTx acute vasoreactivity testing (AVT, 88%) in patients with elevated PVR. Half (51%) reported defining a PVR cutoff for HTx eligibility as ≤6 WU m 2 (56%) post‐AVT (84%). The highest post‐AVT PVR ever accepted for HTx ranged from 3–14.4 (median 6) WU m 2 . To treat elevated pre‐transplant PVR, phosphodiesterase type 5 inhibitors are most common (65%) followed by oxygen (31%), nitric oxide (14%), endothelin receptor antagonists (11%), and prostacyclins (6%). Nearly a third (31%) do not routinely use pulmonary vasodilators without implantation of a left ventricular assist device (LVAD). Case scenarios highlight treatment variability: in a restrictive cardiomyopathy scenario, HTx listing with post‐transplant vasodilator therapy was favored, whereas in a Shone's complex patient with fixed PVR, LVAD ± pulmonary vasodilators followed by repeat catheterization was most common. Management of dilated cardiomyopathy with reactive PVR was variable. Most continue vasodilator therapy until HTx (16%), PVR normalizes (16%) or ≤6 months.
Conclusions
Management of elevated PVR in children awaiting HTx is heterogenous. Evidence‐based guidelines are needed to allow for longitudinal determination of optimal outcomes and standardized care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics (Cardiology), Stanford University School of Medicine, Palo Alto, California, USA.
- Department of Experimental Medical Science, Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
- The Pediatric Heart Center, Skane University Hospital, Lund, Sweden.
- Department of Pediatrics, Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
- Department of Clinical Sciences, Anesthesiology and Intensive Care, Lund University, Lund, Sweden.
ORCID-Profile: Rachel K Hopper, Oscar van der Have, Seth A Hollander, Anne I Dipchand, Valeria Perez de Sa, Jeffrey A Feinstein, Karin Tran-Lundmark
Zitieren
APA
Hopper, R. K., van der Have, O., Hollander, S. A., Dipchand, A. I., Perez de Sa, V., Feinstein, J. A., & Tran-Lundmark, K. (2023). International practice heterogeneity in pre‐transplant management of pulmonary hypertension related to pediatric left heart disease. Pediatric Transplantation. https://doi.org/10.1111/petr.14461
Vancouver
Hopper RK, van der Have O, Hollander SA, Dipchand AI, Perez de Sa V, Feinstein JA, et al. International practice heterogeneity in pre‐transplant management of pulmonary hypertension related to pediatric left heart disease. Pediatric Transplantation. 2023. doi:10.1111/petr.14461
BibTeX
@article{Hopper2023,
author = {Hopper, Rachel K and van der Have, Oscar and Hollander, Seth A and Dipchand, Anne I and Perez de Sa, Valeria and Feinstein, Jeffrey A and Tran-Lundmark, Karin},
title = {International practice heterogeneity in pre‐transplant management of pulmonary hypertension related to pediatric left heart disease},
journal = {Pediatric Transplantation},
year = {2023},
doi = {10.1111/petr.14461}
}
EUVIMED